Alpha-type 1 polarized dendritic cells loaded with apoptotic allogeneic breast cancer cells can induce potent cytotoxic T lymphocytes against breast cancer

Cancer Research and Treatment

Volumn 43, Issue 1, 2011, Pages 56-66

  Park, Min Ho ^a   Yang, Deok Hwan ^a   Kim, Mi Hyun ^a   Jang, Jae Hong ^a   Jang, Yoon Young ^a,b   Lee, Youn Kyung ^a   Jin, Chun Ji ^a,b   Pham, Than Nhan Nguyen ^a   Thi, Truc Anh Nguyen ^a,b   Lim, Mi Seon ^a,b   Lee, Hyun Ju ^a,b   Hong, Cheol Yi ^a   Yoon, Jung Han ^a,b   Lee, Je Jung ^a,b  

^a Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Allogeneic; Breast neoplasms; Cytotoxic T lymphocytes; Dendritic cells; Immunotherapy

Indexed keywords

EID: 84859151435     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2011.43.1.56     Document Type: Article

References (25)

1. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003;8:541-52.
2. Anderson KS. Tumor vaccines for breast cancer. Cancer Invest. 2009;27:361-8.
3. Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther. 2007;7:1225-41.
4. Chaudhuri S, Cariappa A, Tang M, Bell D, Haber DA, Isselbacher KJ, et al. Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci U S A. 2000;97:11451-4.
5. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, et al. Existent Tcell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 1994;54:16-20.
6. Jerome KR, Domenech N, Finn OJ. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol. 1993;151:1654-62.
7. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet. 2005;366:318-20.
8. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-52.
9. Reid DC. Dendritic cells and immunotherapy for malignant disease. Br J Haematol. 2001;112:874-87.
10. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64:5934-7.
11. Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol. 2008;84:319-25.
12. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res. 2000;6:1693-701.
13. 2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2002;8:3407-18.
14. Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res. 2004;10:4688-98.
15. Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004;125:343-52.
16. Lee JJ, Choi BH, Kang HK, Park MS, Park JS, Kim SK, et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leuk Lymphoma. 2007;48:2022-31.
17. + T-cell immunity. J Immunother. 2006;29:545-57.
18. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 2008;68:5972-8.
19. Takei M, Tachikawa E, Hasegawa H, Lee JJ. Dendritic cells maturation promoted by M1 and M4, end products of steroidal ginseng saponins metabolized in digestive tracts, drive a potent Th1 polarization. Biochem Pharmacol. 2004;68:441-52.
20. Trepiakas R, Pedersen AE, Met O, Hansen MH, Berntsen A, Svane IM. Comparison of alpha-type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine. 2008;26:2824-32.
21. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
22. Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 2001;61:5697-702.
23. + T cells. Cancer Immunol Immunother. 2006;55:131-9.
24. Delirezh N, Moazzeni SM, Shokri F, Shokrgozar MA, Atri M, Kokhaei P. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro. Cell Immunol. 2009;257:23-31.
25. Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother. 2006;55:819-29.